Eye Therapy News
The Art of Eyes
Thu, 07 Aug 2014 14:23:19 +0000
The eye is an object of great beauty as shown by the Ophthalmologist in their July/August 2014 issue. This month’s issue features a photo essay called The Art of the Eyes and includes examples of the work from a number research labs capturing the complex and beautiful detail of the eye and its cells. The essay includes images […]Read more...
Tue, 05 Aug 2014 16:02:34 +0000
Dr Yoshiki Sasai (1962 – 2014) It is with great sadness today that we remember and pay tribute to our collaborator Dr Yoshiki Sasai. Yoshiki was a world leading stem cell researcher and Deputy Director of the Riken Center for Developmental Biology in Kobe, Japan. Through his hard work and dedication over many years, Yoshiki […]Read more...
International Clinical Trials Day: Our Work in Summary
Tue, 20 May 2014 15:03:41 +0000
Introduction Today, 20 May 2014, is International Clinical Trials Day. This landmark day remembers the pioneering work of James Lind a Scottish naval physician who, in the 1700s, conducted the first controlled clinical study that identified that citrus fruit (containing Vitamin C) was effective in treating scurvy. Each year, a number of organisations mark this […]Read more...
A profile of Prof. Robin Ali by MRC insight
Professor Robin Ali is an MRC-funded scientist working at the forefront of not one, but two, fields of regenerative medicine: gene and stem cell therapy. Katherine Nightingale caught up with Robin at UCL’s Institute of Ophthalmology to find out more about his work.
Restoring vision in night blindness: Mice point way to stem cell therapy
Professor Robin Ali and his team at the UCL Institute of Ophthalmology have announced the first demonstration that transplanted retinal rod cells can improve vision in mice with night-blindness, publishing the results of their study in the prestigious science journal Nature.
Prof. Robin Ali named as Visionary of the Quarter by European Vision Institute
Gene therapy is a powerful new approach for the treatment of eye disease. We aim to develop gene therapy not only for a number of relatively rare, but currently untreatable, inherited retinopathies, but also to develop more effective treatments for common ocular disorders involving neovascularisation and inflammation.
Interview with Prof. James Bainbridge by the NIHR
James Bainbridge is a Wellcome Advanced Fellow and consultant surgeon. He has an established programme of translational research, developing new molecular treatments for retinal disorders. He is principal investigator for the first clinical trial of gene therapy for inherited eye disease. He is leader of the diabetes research theme for the NIHR Biomedical Research Centre.
Page last modified on 03 jan 13 10:55